LeMaitre Vascular posts strong Q2 2026 results

LeMaitre Vascular reported strong preliminary, unaudited Q2 2026 results.

Rhea-AI Filing Summary

LeMaitre Vascular reported strong preliminary, unaudited Q2 2026 results. Net sales were about $70.4M versus $64.2M a year earlier, with net income of $17.1M and diluted EPS of $0.74 versus $0.60. Gross margin reached 72.1%, up 210 bps, and adjusted EBITDA was $22.8M, up 20%.

Growth was led by Artegraft sales up 34%, record grafts, shunts and patches, and double-digit gains in EMEA and APAC. Organic growth excluding catheters was 12%; catheters declined 11% after prior-year recall overstocking. Cash and short-term marketable securities totaled roughly $376M and stockholders’ equity was $420.3M.

The board declared a $0.25 per-share quarterly dividend payable September 3, 2026 and previously authorized up to $100M of share repurchases through February 2027. Guidance calls for 2026 sales of $274.3M–$278.3M (midpoint $276.3M, about 11% growth) and EPS of $2.84–$2.94 (midpoint $2.89), implying 15% GAAP and 21% adjusted EPS growth versus 2025.

Positive

• Earnings and EPS grew strongly: Q2 2026 net income rose to $17.1M and diluted EPS to $0.74, both up more than 20% year over year, while adjusted EBITDA increased 20%, indicating broad profitability gains.
• Double-digit 2026 outlook: Full-year 2026 guidance targets midpoint sales of $276.3M (+11% reported and organic) and EPS of $2.89 (+15% GAAP, +21% adjusted), signaling expected continued growth.
• Artegraft and international momentum: Artegraft sales grew 34% and now represent 21% of sales, with approvals in 56 countries and double-digit regional growth in EMEA and APAC.
• Capital returns plus strong liquidity: The company holds about $376M in cash and short-term marketable securities, while authorizing up to $100M of share repurchases and paying a quarterly dividend of $0.25 per share.

Negative

• None.

Filing Explained

At June 30, 2026, the company reported convertible senior notes, and identified the potential dilutive effect of a conversion as a risk; the filing does not report a conversion.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q2 2026 Net Sales: $70,382 Q2 2026 Net Income: $17,050 Q2 2026 Diluted EPS: $0.74 +5 more

8 metrics

Q2 2026 Net Sales $70,382 Net sales for the three months ended June 30, 2026 (amounts in thousands)

Q2 2026 Net Income $17,050 Net income for the three months ended June 30, 2026 (amounts in thousands)

Q2 2026 Diluted EPS $0.74 Diluted earnings per share for the three months ended June 30, 2026

Q2 2026 Gross Margin 72.1% Gross margin for the three months ended June 30, 2026, up 210 basis points year over year

Q2 2026 Adjusted EBITDA $22,767 Adjusted EBITDA for the three months ended June 30, 2026 (amounts in thousands), up 20%

2026 Sales Guidance Midpoint $276.3mm Full-year 2026 sales guidance midpoint with +11% reported and organic growth

2026 EPS Guidance Midpoint $2.89 Full-year 2026 EPS guidance midpoint, +15% GAAP and +21% adjusted versus 2025

Share Repurchase Authorization $100.0mm Board-authorized common stock repurchase capacity through February 18, 2027

Key Terms

organic growth, Adjusted EBITDA, convertible senior notes, employee retention credit, +2 more

6 terms

organic growth financial

"Q2 organic growth was 12% excluding catheters."

Organic growth is the increase in a company's sales or profits that comes from its own activities, such as selling more products or services, rather than through acquisitions or mergers. It is like a plant growing taller on its own, without needing outside help. For investors, it indicates the company's ability to expand steadily and sustainably through its existing business efforts.

Adjusted EBITDA financial

"Reconciliation between GAAP and Non-GAAP Adjusted EBITDA"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

convertible senior notes financial

"Convertible senior notes, net | | | 169,091"

Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.

employee retention credit financial

"Impact of employee retention credit | | | (3,380 | )"

A government-provided payroll tax credit that reimburses employers for a portion of wages paid to staff during qualifying downturns or disruptions, designed to encourage businesses to keep employees on the payroll. For investors, it matters because the credit improves a company’s cash flow and reduces payroll expenses—like a temporary government subsidy that boosts short-term profits and may change the company’s reported tax liabilities and cash reserves, which can affect valuation and risk assessments.

non-GAAP financial measures financial

"Use of Non-GAAP Financial Measures LeMaitre management believes"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

peripheral vascular disease medical

"devices, implants, and services for the treatment of peripheral vascular disease"

Earnings Snapshot

Net sales: $70,382 · Guidance included

Quarter ended June 30, 2026

Net sales $70,382 up from $64,232 for the quarter ended June 30, 2025

Net income $17,050 up from $13,779 for the quarter ended June 30, 2025

Diluted EPS $0.74 up from $0.60 for the quarter ended June 30, 2025

Gross margin 72.1% up 210 basis points year over year

Guidance

For 2026, the company guides to sales of $274.3M–$278.3M (midpoint $276.3M, about 11% growth), operating income of $75.3M–$78.2M (midpoint $76.8M, +13% GAAP and +19% adjusted), and EPS of $2.84–$2.94 (midpoint $2.89, +15% GAAP and +21% adjusted versus 2025).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did LeMaitre Vascular (LMAT) perform financially in Q2 2026?

LeMaitre Vascular reported Q2 2026 net sales of $70.4M and net income of $17.1M. Diluted EPS was $0.74 versus $0.60 a year earlier, with gross margin of 72.1% and adjusted EBITDA of $22.8M, up 20% year over year.

What sales guidance did LeMaitre Vascular (LMAT) provide for 2026?

For 2026, LeMaitre projects sales of $274.3M–$278.3M, with a midpoint of $276.3M. This midpoint implies about 11% total and organic growth versus 2025, reflecting expectations for continued expansion across products and regions.

What is LeMaitre Vascular (LMAT)'s EPS guidance for full-year 2026?

LeMaitre expects 2026 EPS of $2.84–$2.94, midpoint $2.89. The company states this represents 15% GAAP EPS growth and 21% adjusted EPS growth versus 2025, excluding the prior-year employee retention tax credit.

What dividend did LeMaitre Vascular (LMAT) declare and when will it be paid?

The board approved a quarterly dividend of $0.25 per share of common stock. It will be paid on September 3, 2026 to shareholders of record as of August 20, 2026, continuing the company’s cash-return program.

What is LeMaitre Vascular (LMAT)'s current share repurchase authorization?

On February 19, 2026, the board authorized repurchases of up to $100.0M of common stock. The program may be suspended or discontinued and is scheduled to conclude on February 18, 2027, unless the board extends it.

How strong is LeMaitre Vascular (LMAT)'s balance sheet at June 30, 2026?

As of June 30, 2026, LeMaitre held $26.6M in cash and $349.6M in short-term marketable securities. Total assets were $640.5M, stockholders’ equity was $420.3M, and convertible senior notes totaled $169.1M.

What were the key growth drivers for LeMaitre Vascular (LMAT) in Q2 2026?

Q2 growth was driven by Artegraft sales up 34%, record graft, carotid shunt and patch sales, and regional growth of +18% in EMEA, +18% in APAC and +5% in the Americas. Organic growth excluding catheters was 12%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 04:39 PM Accepted by SEC EDGAR 08/04/2026 - 04:39 PM Learn about SEC filing dates

LEMAITRE VASCULAR INC false 0001158895 0001158895 2026-08-04 2026-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2026

LeMaitre Vascular, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-33092

Delaware		04-2825458
(State or other jurisdiction of incorporation)		(IRS Employer Identification No.)

63 Second Avenue

Burlington, MA 01803

(Address of principal executive offices, including zip code)

781-221-2266

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class		Trading symbol		Name of exchange on which registered
Common stock, $0.01 par value per share		LMAT		The Nasdaq Global Market

Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 4, 2026, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Report.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Disclaimer on Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Item 9.01. Financial Statements and Exhibits.

The following exhibits are furnished or filed as part of this Report, as applicable:

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued by LeMaitre Vascular, Inc. on August 4, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						LeMaitre Vascular, Inc.
Date: August 4, 2026				By:		Dorian P. LeBlanc
						/s/ DORIAN P. LEBLANC
						Chief Financial Officer

Exhibit Index

Exhibit No.		Description
99.1		Press release issued by LeMaitre Vascular, Inc. on August 4, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Exhibit 99.1

LeMaitre Q2 2026 Financial Results

BURLINGTON, MA, August 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

Q2 2026:

• Sales $70.4mm, +10% (+10% organic) vs. Q2 2025

• Gross margin 72.1% (+210 bps)

• Op. income $20.4mm (+26%)

• Op. margin 29%

• EPS $0.74 (+23%)

• Cash up $9.0mm sequentially to $376.2mm

Artegraft sales increased 34% in the quarter. Grafts (+23%), carotid shunts (+18%), and patches (+4%) each posted records, as did EMEA (+18%), APAC (+18%) and the Americas (+5%). Catheters were down 11% in the quarter due to recall-driven overstocking in Q2 2025. Q2 organic growth was 12% excluding catheters.

Gross margin of 72.1% was up 210 bps due to higher prices, mix shift, and operational efficiencies. Operating income of $20.4mm (+26%) also benefited from headcount restraint: 660 at 6/30/2026 vs. 658 at 6/30/2025.

Chairman/CEO George LeMaitre said, “Our focus on the Artegraft international launch paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go direct in new countries and we’re now undertaking six international warehouse expansions. $376m of cash provides strategic optionality.”

Business Outlook

		Q3 2026 Guidance		Q4 2026 Guidance		Full Year Guidance
Sales		$66.3mm - $68.3mm (Mid $67.3mm, +10%, +11% org.)		$71.1mm - $73.1mm (Mid $72.1mm, +12%, +12% org.)		$274.3mm - $278.3mm (Mid $276.3mm, +11%, +11% org.)
Gross Margin		72.2%		72.6%		72.4%
Op. Income		$17.3mm - $18.8mm (Mid $18.1mm, -11%, +7% adj.)		$19.8mm - $21.2mm (Mid $20.5mm, +9%)		$75.3mm - $78.2mm (Mid $76.8mm, +13%, +19% adj.)
Op. Margin (Mid)		27%		29%		28%
EPS		$0.66 - $0.71 (Mid $0.69, -9%, +11% adj.)		$0.75 - $0.81 (Mid $0.78, +15%)		$2.84 - $2.94 (Mid $2.89, +15%, +21% adj.)

* Q3 2025 results included a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP projected results is included.

Quarterly Dividend

On July 28, 2026, the Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on September 3, 2026, to stockholders of record on August 20, 2026.

Share Repurchase Program

On February 19, 2026, the Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company’s website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company’s website.

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for operating income and EPS guidance adjusted to exclude the effects of the employee retention tax credit received in 2025. Management believes that viewing projected growth in operating income and EPS excluding those effects provides an alternative and meaningful view of the Company’s projected profitability.

Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

Forward-Looking Statements

The Company’s current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other regulatory reviews, affecting our ability to market and sell our products domestically and internationally; competition from other medical device companies and alternative medical technologies; our ability to source, acquire, and integrate acquisitions; our dependence on sole- or limited-source suppliers; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters; the occurrence of

product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT:

Gregory Manker

Director of Business Development and Investor Relations

ir@LEMAITRE.COM

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands)

		June 30, 2026				December 31, 2025
		(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	26,625			$	28,244
Short-term marketable securities			349,615				330,876
Accounts receivable, net			35,682				33,610
Inventory and other deferred costs			70,503				70,422
Prepaid expenses and other current assets			5,872				5,080
Total current assets			488,297				468,232
Property and equipment, net			29,591				26,997
Right-of-use leased assets			19,998				15,762
Goodwill			65,945				65,945
Other intangibles, net			30,544				33,089
Deferred tax assets			734				759
Other assets			5,440				4,906
Total assets		$	640,549			$	615,690
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		$	3,236			$	3,646
Accrued expenses			22,880				29,411
Acquisition-related obligations			380				322
Lease liabilities - short-term			3,439				2,944
Total current liabilities			29,935				36,323
Convertible senior notes, net			169,091				168,645
Lease liabilities - long-term			17,724				14,003
Deferred tax liabilities			1,998				1,735
Other long-term liabilities			1,459				1,468
Total liabilities			220,207				222,174
Stockholders’ equity
Common stock			245				244
Additional paid-in capital			236,161				228,407
Retained earnings			206,017				184,715
Accumulated other comprehensive loss			(4,165	)			(2,411	)
Treasury stock			(17,916	)			(17,439	)
Total stockholders’ equity			420,342				393,516
Total liabilities and stockholders’ equity		$	640,549			$	615,690

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

(unaudited)

		For the three months ended								For the six months ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Net sales		$	70,382			$	64,232			$	136,933			$	124,103
Cost of sales			19,618				19,258				37,773				37,709
Gross profit			50,764				44,974				99,160				86,394
Operating expenses:
Sales and marketing			14,408				14,895				28,923				29,107
General and administrative			11,110				10,396				23,156				20,883
Research and development			4,847				3,541				8,907				7,636
Total operating expenses			30,365				28,832				60,986				57,626
Income from operations			20,399				16,142				38,174				28,768
Other income (expense):
Investment income			3,386				2,980				6,710				5,883
Interest expense			(1,302	)			(1,299	)			(2,602	)			(2,589	)
Other income (loss), net			(294	)			247				(421	)			249
Income before income taxes			22,189				18,070				41,861				32,311
Provision for income taxes			5,139				4,291				9,132				7,521
Net income		$	17,050			$	13,779			$	32,729			$	24,790
Earnings per share of common stock
Basic		$	0.75			$	0.61			$	1.43			$	1.10
Diluted		$	0.74			$	0.60			$	1.42			$	1.08
Weighted - average shares outstanding:
Basic			22,858				22,614				22,830				22,592
Diluted			24,531				22,892				24,505				22,896
Cash dividends declared per common share		$	0.25			$	0.20			$	0.50			$	0.40

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(amounts in thousands)

(unaudited)

		For the six months ended
		June 30, 2026				June 30, 2025
Operating activities
Net income		$	32,729			$	24,790
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization			5,285				5,200
Stock-based compensation			4,027				3,990
Amortization of issuance costs on convertible notes			446				433
Non-cash investment income			(805	)			—
Provision for inventory write-downs			1,548				1,030
Provision for credit losses			333				337
Foreign currency transaction effect on income			145				(279	)
Changes in operating assets and liabilities:
Accounts receivables			(2,877	)			(5,299	)
Inventory and other deferred costs			(1,935	)			(3,454	)
Prepaid expenses and other assets			(1,363	)			1,676
Accounts payable and other liabilities			(6,475	)			(1,250	)
Accrued interest			—				2,156
Net cash provided by operating activities			31,058				29,330
Investing activities
Purchases of short-term marketable securities			(231,434	)			(17,849	)
Purchases of property and equipment			(5,096	)			(2,725	)
Payments related to acquisitions, net of cash acquired			(158	)			(95	)
Proceeds from short-term marketable securities			212,489				—
Net cash used in investing activities			(24,199	)			(20,669	)
Financing activities
Proceeds from stock option exercises			3,728				3,072
Deferred payments for acquisitions			(95	)			(1,433	)
Payment of withholding taxes in connection with net settlement of equity awards			(477	)			(605	)
Common stock cash dividend paid			(11,427	)			(9,037	)
Net cash used in financing activities			(8,271	)			(8,003	)
Effect of exchange rate changes on cash and cash equivalents			(207	)			909
Net (decrease) increase in cash and cash equivalents			(1,619	)			1,567
Cash and cash equivalents at beginning of period			28,244				25,610
Cash and cash equivalents at end of period		$	26,625			$	27,177

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

		For the three months ended																For the six months ended
		June 30, 2026								June 30, 2025								June 30, 2026								June 30, 2025
		$				%				$				%				$				%				$				%
Net Sales by Geography
Americas		$	43,454				62	%		$	41,321				64	%		$	85,050				62	%		$	80,279				65	%
Europe, Middle East and Africa			22,137				31	%			18,840				29	%			42,424				31	%			35,799				29	%
Asia Pacific			4,791				7	%			4,071				7	%			9,459				7	%			8,025				6	%
Total Net Sales		$	70,382				100	%		$	64,232				100	%		$	136,933				100	%		$	124,103				100	%

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

		For the three months ended								For the six months ended
		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
Reconciliation between GAAP and Non-GAAP Adjusted EBITDA
Net income as reported		$	17,050			$	13,779			$	32,729			$	24,790
Interest (income) expense, net			(2,084	)			(1,681	)			(4,108	)			(3,294	)
Amortization and depreciation expense			2,662				2,648				5,285				5,200
Provision for income taxes			5,139				4,291				9,132				7,521
Adjusted EBITDA		$	22,767			$	19,037			$	43,038			$	34,217
Adjusted EBITDA percentage increase			20	%											26	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

Reconciliation between GAAP and Non-GAAP sales growth:
For the three months ended June 30, 2026
Net sales as reported		$	70,382
Impact of currency exchange rate fluctuations			(352	)
Adjusted net sales						$	70,030
For the three months ended June 30, 2025
Net sales as reported		$	64,232
Net impact of divestitures excluding currency			(365	)
Adjusted net sales						$	63,867
Adjusted net sales increase for the three months ended June 30, 2026						$	6,163				10	%
Reconciliation between GAAP and Non-GAAP sales growth (excluding catheters):
For the three months ended June 30, 2026
Net sales as reported		$	70,382
Catheter net sales as reported			(6,895	)
Impact of currency exchange rate fluctuations			(352	)
Adjusted net sales						$	63,135
For the three months ended June 30, 2025
Net sales as reported		$	64,232
Catheter net sales as reported			(7,754	)
Adjusted net sales						$	56,478
Adjusted net sales increase (excluding catheters) for the three months ended June 30, 2026						$	6,657				12	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
For the three months ending September 30, 2026
Net sales per guidance (midpoint)		$	67,300
Impact of currency exchange rate fluctuations			489
Adjusted projected net sales						$	67,789
For the three months ended September 30, 2025
Net sales as reported		$	61,046
Adjusted net sales						$	61,046
Adjusted projected net sales increase for the three months ending September 30, 2026						$	6,743				11	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
For the three months ending December 31, 2026
Net sales per guidance (midpoint)		$	72,100
Impact of currency exchange rate fluctuations			162
Adjusted projected net sales						$	72,262
For the three months ended December 31, 2025
Net sales as reported		$	64,453
Adjusted net sales						$	64,453
Adjusted projected net sales increase for the three months ending December 31, 2026						$	7,809				12	%
Reconciliation between GAAP and Non-GAAP projected sales growth:
For the year ending December 31, 2026
Net sales per guidance (midpoint)		$	276,300
Impact of currency exchange rate fluctuations			(1,749	)
Adjusted projected net sales						$	274,551
For the year ended December 31, 2025
Net sales as reported		$	249,602
Net impact of divestitures excluding currency			(1,839	)
Adjusted net sales						$	247,763
Adjusted projected net sales increase for the year ending December 31, 2026						$	26,788				11	%

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

Reconciliation between GAAP and Non-GAAP projected operating income growth:
For the three months ending September 30, 2026
Operating income per guidance (midpoint)		$	18,100
Projected operating income						$	18,100
For the three months ended September 30, 2025
Operating income as reported		$	20,312
Impact of employee retention credit			(3,380	)
Adjusted operating income						$	16,932
Adjusted projected operating income increase for the three months ending September 30, 2026						$	1,168				7	%
Reconciliation between GAAP and Non-GAAP projected operating income growth:
For the year ending December 31, 2026
Operating income per guidance (midpoint)		$	76,800
Projected operating income						$	76,800
For the year ended December 31, 2025
Operating income as reported		$	67,912
Impact of employee retention credit			(3,380	)
Adjusted operating income						$	64,532
Adjusted projected operating income increase for the year ending December 31, 2026						$	12,268				19	%
Reconciliation between GAAP and Non-GAAP earnings per share growth:
For the three months ending September 30, 2026
Earnings per share per guidance (midpoint)		$	0.69
Projected earnings per share						$	0.69
For the three months ended September 30, 2025
Earnings per share as reported		$	0.75
Impact of employee retention credit			(0.13	)
Adjusted earnings per share						$	0.62
Adjusted projected earnings per share increase for the three months ending September 30, 2026						$	0.07				11	%
Reconciliation between GAAP and Non-GAAP earnings per share growth:
For the year ending December 31, 2026
Earnings per share per guidance (midpoint)		$	2.89
Projected earnings per share						$	2.89
For the year ended December 31, 2025
Earnings per share as reported		$	2.52
Impact of employee retention credit			(0.14	)
Adjusted earnings per share						$	2.38
Adjusted projected earnings per share increase for the year ending December 31, 2026						$	0.51				21	%

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 219.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB